SCHEMBL22747549

SCHEMBL22747549

COC(=O)/C=C/c1c(-c2ccccc2)[nH]c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 1/20 0.53
▸ MTNR1B P49286 1/20 0.53
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ MAPT P10636 3/20 0.49
▸ LMNA P02545 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ PDE4B Q07343 1/20 0.46
▸ TUBB4A P04350 1/20 0.45
▸ TUBB P07437 1/20 0.45
▸ TUBA3C P0DPH7 1/20 0.45
▸ TUBA1B P68363 1/20 0.45
▸ TUBA4A P68366 1/20 0.45
▸ TUBB4B P68371 1/20 0.45
▸ TUBB3 Q13509 1/20 0.45
▸ TUBB2A Q13885 1/20 0.45
▸ TUBB8 Q3ZCM7 1/20 0.45
▸ TUBA3E Q6PEY2 1/20 0.45
▸ TUBA1A Q71U36 1/20 0.45
▸ TUBA1C Q9BQE3 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29033496 1.00 MTNR1A (0.53) MTNR1AMTNR1BMEN1KMT2AMAPT
SCHEMBL29033495 0.90 PTGS2 (0.46) MTNR1AMTNR1BMEN1KMT2AMAPT
SCHEMBL22161378 0.90 TUBB4A (0.49) MTNR1AMTNR1BMEN1KMT2AMAPT
SCHEMBL29033515 0.85 MEN1 (0.46) MTNR1AMTNR1BMEN1KMT2AMAPT
SCHEMBL29033499 0.85 CCNC (0.50) MTNR1AMTNR1BMEN1KMT2AMAPT
SCHEMBL29033517 0.84 MEN1 (0.63) MTNR1AMTNR1BMEN1KMT2AMAPT
SCHEMBL18932674 0.83 KMT2A (0.66) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL22747530 0.81 KDM4E (0.47) MTNR1AMTNR1BMAPTALDH1A1SMN1; SMN2
SCHEMBL29033534 0.81 MAPT (0.47) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL8803840 0.79 KMT2A (0.49) MTNR1AMTNR1BMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-08-31 — — US disclosed
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-08-31 — — US disclosed
US-11618746-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-04-04 — — US disclosed
US-20200377479-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME Vertex Pharmacéuticals Incorporated 2020-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, SAAL1 MTNR1A 4217/4885MTNR1B 4033/4885MEN1 3255/4885
US-11618746-B2 Inhibitors of APOL1 and methods of using same APOL1, APOB, NPC1L1 MTNR1A 4205/4885MTNR1B 4176/4885MEN1 3794/4885
US-20200377479-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, SAAL1, LOXL1 MTNR1A 4028/4885MTNR1B 3991/4885MEN1 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback